지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 387 - 394 (8page)
이용수
초록· 키워드
오류제보하기
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with nonalcoholicfatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study wasdesigned to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combinedwith metformin. Methods: Among patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients whohad abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and theclinical and treatment histories of all patients were reviewed. Results: A total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed moreweight loss and more ALT decline than DPP4i group (–2.9 kg vs. –0.4 kg, P=0.005; –21.1 U/L vs. –9.5 U/L, P=0.008, respectively)and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0%vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment forconfounding variables including body weight loss (odds ratio, 3.489; P=0.046). Conclusion: ALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin andthe result was consistent after adjustment for confounding variables including body weight loss.
목차
등록된 정보가 없습니다.
참고문헌 (34)
참고문헌 신청
Whiting DR / 2011 / IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 / Diabetes Res Clin Pract 94:311~321
Younossi ZM / 2016 / Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes / Hepatology 64:73~84
한광협 / 2016 / The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter / Yonsei Medical Journal 57(4):885~892
Hazlehurst JM / 2016 / Non-alcoholic fatty liver disease and diabetes / Metabolism 65:1096~1108
Targher G / 2007 / Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients / Diabetes Care 30:1212~1218
Younossi ZM / 2016 / Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes / Hepatology 64:73~84
한광협 / 2016 / The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter / Yonsei Medical Journal 57(4):885~892
Hazlehurst JM / 2016 / Non-alcoholic fatty liver disease and diabetes / Metabolism 65:1096~1108
Targher G / 2007 / Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients / Diabetes Care 30:1212~1218
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
Journal of Obesity & Metabolic Syndrome
2017 .01
-
Clinical studies of dapagliflozin in pediatric patients: a rapid review
Annals of Pediatirc Endocrinology & Metabolism
2022 .12
-
제2형 당뇨병 환자에서 Dapagliflozin이 혈당과 심혈관계질환 위험인자에 미치는 영향 및 안전성
한국임상약학회지
2017 .01
-
비알콜성 지방간을 가진 제2형 당뇨병 환자에서 지방간 개선에 대한 Dapagliflozin의 효과
병원약사회지
2021 .01
-
제 2형 당뇨병 환자에서 Dapagliflozin의 안전성 평가
병원약사회지
2019 .01
-
Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
Diabetes and Metabolism Journal
2024 .09
-
Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2022 .11
-
급성 뇌경색을 동반한 당뇨 환자에게 Dapagliflozin 투여 후 발생한 급성 신손상 1예
대한내과학회지
2020 .12
-
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
Diabetes and Metabolism Journal
2021 .01
-
Use of dapagliflozin in patients with advanced diabetic kidney disease
Kidney Research and Clinical Practice
2018 .01
-
Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease
Journal of Obesity & Metabolic Syndrome
2020 .01
-
제2형 당뇨병 환자에서 Metformin과 병용한 Sodium-Glucose Cotransporter 2 Inhibitors와 Dipeptidyl Peptidase 4 Inhibitors의 효능 비교
병원약사회지
2020 .01
-
Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711-7)
Diabetes and Metabolism Journal
2019 .01
-
Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711-7)
Diabetes and Metabolism Journal
2019 .01
-
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Korean Circulation Journal
2021 .01
-
Metformin에 추가로 병용되는 SGLT2 inhibitors의 효능과 안전성에 관한 고찰
한국임상약학회지
2018 .01
-
DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
Endocrinology and Metabolism
2022 .12
-
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
International Neurourology Journal
2020 .01
-
Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea
Endocrinology and Metabolism
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0